{"id":"metronidazole-gel-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning at application site"},{"rate":null,"effect":"Dryness or peeling"},{"rate":null,"effect":"Metallic taste (if absorbed systemically)"}]},"_chembl":null,"_dailymed":{"setId":"585d2553-e19f-4227-82db-e4c2034863bf","title":"METRONIDAZOLE VAGINAL GEL (METRONIDAZOLE VAGINAL GEL, 1.3 %) GEL [ENCUBE ETHICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole is a prodrug that is activated by anaerobic organisms and protozoans to form reactive intermediates that bind to and damage DNA, preventing replication and transcription. This mechanism is particularly effective against anaerobic bacteria and certain parasites. The topical gel formulation delivers the drug directly to affected skin areas, minimizing systemic absorption.","oneSentence":"Metronidazole disrupts bacterial and protozoal DNA by generating reactive oxygen species and damaging nucleic acids, leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:07.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rosacea (topical)"},{"name":"Bacterial vaginosis (topical)"},{"name":"Perioral dermatitis (topical)"}]},"trialDetails":[{"nctId":"NCT05929794","phase":"PHASE4","title":"Pharmacokinetics of Transdermal Metronidazole","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Iowa","startDate":"2024-02-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT07392047","phase":"PHASE4","title":"Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2026-02","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT06434519","phase":"NA","title":"Metronidazole SC Penetrance With Moisturizers","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-03","conditions":"Rosacea, Erythematotelangiectatic","enrollment":21},{"nctId":"NCT06027151","phase":"NA","title":"Comparing the Efficacy of Metronidazole and Minocycline Gels for the Treatment of Diabetic Periodontitis Patients","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2022-10-06","conditions":"Periodontitis, Diabetes Mellitus","enrollment":380},{"nctId":"NCT07123792","phase":"NA","title":"Effect of Intracanal Medicaments on Post-Operative Pain in Symptomatic Apical Periodontitis: An RCT","status":"COMPLETED","sponsor":"HITEC-Institute of Medical Sciences","startDate":"2024-06-03","conditions":"Periodontal Diseases","enrollment":480},{"nctId":"NCT05608564","phase":"NA","title":"Local and Systemic Antimicrobials in Non-surgical Periodontal Therapy","status":"COMPLETED","sponsor":"University of Belgrade","startDate":"2023-01-17","conditions":"Periodontitis","enrollment":38},{"nctId":"NCT06570863","phase":"NA","title":"To Evaluate the Effects of Systemic Probiotics & Antibiotics and Local Application of Antibiotics As an Adjuvant to NSPT","status":"COMPLETED","sponsor":"Dr fizza khalid","startDate":"2022-07-01","conditions":"Periodontitis, Adult","enrollment":120},{"nctId":"NCT06752889","phase":"NA","title":"Clinical and Radiographic Evaluation of Zinc Oxide Modified 3Mixtatin Versus Zical in Root Canal Treatment of Necrotic Primary Molars.","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":"Necrotic Pulp, Primary Teeth","enrollment":34},{"nctId":"NCT06659380","phase":"NA","title":"Probiotic Efficacy in Postmenopausal Women with Bacterial Vaginosis","status":"RECRUITING","sponsor":"Hasanuddin University","startDate":"2024-06-26","conditions":"Bacterial Vaginosis (BV), Menopause","enrollment":12},{"nctId":"NCT01020396","phase":"PHASE1, PHASE2","title":"Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Bacterial Vaginosis","enrollment":579},{"nctId":"NCT04149327","phase":"PHASE4","title":"Systemic Amoxicillin Plus Metronidazole in Peri-implantitis Treatment","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2012-08-01","conditions":"Peri-implantitis, Periodontal Diseases","enrollment":62},{"nctId":"NCT06305546","phase":"NA","title":"Comparisons Of Different Antiplaque Agents On Gingivitis In Orthodontic Patients","status":"COMPLETED","sponsor":"Anam Sattar","startDate":"2023-04-01","conditions":"Gingivitis","enrollment":80},{"nctId":"NCT04979832","phase":"PHASE1, PHASE2","title":"GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery","status":"UNKNOWN","sponsor":"Zealand University Hospital","startDate":"2021-09-06","conditions":"Pouchitis","enrollment":18},{"nctId":"NCT01426269","phase":"PHASE4","title":"Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-09","conditions":"Rosacea","enrollment":235},{"nctId":"NCT01139008","phase":"PHASE4","title":"Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-06","conditions":"Skin Manifestations","enrollment":80},{"nctId":"NCT01139047","phase":"PHASE4","title":"Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-06","conditions":"Skin Manifestations","enrollment":77},{"nctId":"NCT00668655","phase":"","title":"An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-02","conditions":"Rosacea","enrollment":30},{"nctId":"NCT00436527","phase":"PHASE4","title":"Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08","conditions":"Rosacea","enrollment":26},{"nctId":"NCT03271983","phase":"EARLY_PHASE1","title":"Pharmacokinetics of Metronidazole Dermal Products","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-04-09","conditions":"Bioequivalence","enrollment":7},{"nctId":"NCT02042287","phase":"PHASE4","title":"Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2014-06","conditions":"Bacterial Vaginosis","enrollment":32},{"nctId":"NCT03769688","phase":"PHASE1","title":"Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2022-03","conditions":"Bacterial Vaginosis","enrollment":""},{"nctId":"NCT02236403","phase":"PHASE3","title":"Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2014-10","conditions":"Chronic Blepharitis","enrollment":60},{"nctId":"NCT02393937","phase":"PHASE3","title":"A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea","status":"COMPLETED","sponsor":"bioRASI, LLC","startDate":"2015-02","conditions":"Papulopustular Rosacea, Erythematotelangiectatic Rosacea","enrollment":963},{"nctId":"NCT02308007","phase":"PHASE3","title":"Multi-Center Study of New Medications to Treat Vaginal Infections","status":"COMPLETED","sponsor":"Curatek Pharmaceuticals, LLC","startDate":"2015-06","conditions":"Vaginal Infection","enrollment":475},{"nctId":"NCT02308046","phase":"PHASE3","title":"Multi-Center Study of New Medications to Treat Vaginal Infections","status":"COMPLETED","sponsor":"Curatek Pharmaceuticals, LLC","startDate":"2015-06","conditions":"Vaginal Infection","enrollment":212},{"nctId":"NCT02308033","phase":"PHASE3","title":"Multi-Center Study of New Medications to Treat Vaginal Infections","status":"COMPLETED","sponsor":"Curatek Pharmaceuticals, LLC","startDate":"2015-06","conditions":"Vaginal Infection","enrollment":204},{"nctId":"NCT02602470","phase":"","title":"Preferences & Treatment Satisfaction Drivers in Rosacea Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01-08","conditions":"Rosacea","enrollment":206},{"nctId":"NCT00855595","phase":"PHASE4","title":"Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-02","conditions":"Papulopustular Rosacea","enrollment":207},{"nctId":"NCT02766023","phase":"PHASE2","title":"LACTIN-V Study for Recurrent Bacterial Vaginosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-06-03","conditions":"Bacterial Vaginosis","enrollment":228},{"nctId":"NCT02237950","phase":"PHASE3","title":"Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)","status":"COMPLETED","sponsor":"Starpharma Pty Ltd","startDate":"2014-10-13","conditions":"Bacterial Vaginosis","enrollment":586},{"nctId":"NCT02236156","phase":"PHASE3","title":"Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)","status":"COMPLETED","sponsor":"Starpharma Pty Ltd","startDate":"2014-10-03","conditions":"Bacterial Vaginosis","enrollment":637},{"nctId":"NCT02197182","phase":"EARLY_PHASE1","title":"LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study","status":"TERMINATED","sponsor":"CDA Research Group, Inc.","startDate":"2014-06","conditions":"Bacterial Vaginosis (BV)","enrollment":50},{"nctId":"NCT03142607","phase":"PHASE3","title":"Comparative Evaluation of Chlorhexidine, Metronidazole and Combination Gels on Gingivitis","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2017-02-03","conditions":"Gingivitis","enrollment":90},{"nctId":"NCT02713139","phase":"PHASE3","title":"Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.","status":"WITHDRAWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2013-09","conditions":"Sexual Active Women, Vaginal Discharge","enrollment":""},{"nctId":"NCT01813162","phase":"PHASE1","title":"In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products","status":"COMPLETED","sponsor":"CONRAD","startDate":"2013-12","conditions":"HIV Prevention","enrollment":101},{"nctId":"NCT02052999","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients","status":"COMPLETED","sponsor":"Amorepacific Corporation","startDate":"2013-02","conditions":"Erythematotelangiectatic Rosacea, Papulopustular Rosacea","enrollment":80},{"nctId":"NCT01513863","phase":"PHASE1","title":"A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2011-08","conditions":"Rosacea","enrollment":602},{"nctId":"NCT01938183","phase":"PHASE2","title":"Full-mouth Periodontal Debridement and Metronidazole Gel in Patients With Chronic Periodontitis","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2006-11","conditions":"Chronic Periodontitis","enrollment":30},{"nctId":"NCT01055106","phase":"PHASE2","title":"Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2010-01","conditions":"Vaginosis, Bacterial, Vaginal Infection","enrollment":255},{"nctId":"NCT00249782","phase":"PHASE2","title":"A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Rosacea","enrollment":400},{"nctId":"NCT01020877","phase":"PHASE1","title":"Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-11","conditions":"Healthy","enrollment":38},{"nctId":"NCT00545181","phase":"NA","title":"Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2007-09","conditions":"Bacterial Vaginosis","enrollment":55},{"nctId":"NCT00495313","phase":"PHASE4","title":"Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens","status":"COMPLETED","sponsor":"CollaGenex Pharmaceuticals","startDate":"2007-03","conditions":"Rosacea","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MetroGel® 1%","MetroGel® 1% gel"],"phase":"marketed","status":"active","brandName":"Metronidazole gel 1%","genericName":"Metronidazole gel 1%","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metronidazole disrupts bacterial and protozoal DNA by generating reactive oxygen species, leading to cell death. Used for Rosacea (topical), Bacterial vaginosis (topical), Perioral dermatitis (topical).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}